GLP-1 Telehealth Follow-Up Standards: How Often Should Your Provider Check In?

One of the most significant quality differentiators among GLP-1 telehealth platforms is follow-up care. Some platforms provide structured, regular check-ins with licensed providers. Others prescribe and disappear. Understanding what adequate follow-up looks like helps you evaluate whether your platform is providing care or just selling medication.

During Titration: Monthly Is the Minimum

The titration phase — when your dose increases every 4 weeks — is the highest-risk period for side effects, medication adjustments, and patient dropout. During this phase, follow-up should occur at every dose change, which means approximately monthly for the first 4-5 months.

Each titration follow-up should assess:

• Side effect severity and management — are nausea, constipation, or other GI effects tolerable? Do they warrant dose hold or intervention?
• Weight loss progress — is the patient responding to the medication? Minimal response at therapeutic doses may indicate a need for medication switch or clinical investigation.
• Medication tolerance — can the patient tolerate the next dose increase, or should they hold at the current level?
• Hydration and nutrition adequacy — are they eating and drinking enough? Protein intake assessment.
• Mental health check-in — mood changes, eating behavior shifts, body image concerns

These don't need to be lengthy consultations. A focused 10-15 minute video or phone check-in is sufficient for most patients. But the check-in needs to happen, and it needs to be with someone clinically qualified to make dosing decisions.

During Maintenance: Quarterly Minimum

Once a patient reaches their maintenance dose and is weight-stable, the follow-up cadence can decrease — but it should never stop. The evidence-based minimum for maintenance phase follow-up is every 3 months (quarterly), which should include:

• Weight and metabolic status review
• Side effect reassessment — some side effects emerge or change over time
• Lab work review (at 3-month, 6-month, and annual intervals)
• Medication effectiveness evaluation — is the current dose still appropriate, or could a maintenance dose reduction be considered?
• Refill authorization — tied to clinical review, not automatic

Between Scheduled Visits: Accessibility Matters

Scheduled follow-ups are the framework, but patients need access to clinical guidance between visits. A quality telehealth platform should offer:

Asynchronous messaging — the ability to send questions or concerns to your provider team and receive a response within 24-48 hours (business days). This is the most common and practical between-visit communication method.

Urgent consultation access — for side effects that are severe, unexpected, or potentially dangerous (persistent vomiting, severe abdominal pain, signs of dehydration), a mechanism to reach a provider within hours, not days.

Clear escalation protocols — when to go to urgent care or the ER versus when to message your provider. Patients should know these guidelines from the start of treatment.

What Inadequate Follow-Up Looks Like

These are signs that your platform's follow-up care is insufficient:

• Dose increases are automatic without any clinical review
• You've been on the medication for 3+ months without anyone checking your labs or reviewing your progress
• You can't reach a provider between scheduled visits for clinical questions
• Your "follow-up" is a satisfaction survey or a prescription renewal form, not a clinical evaluation
• You've never spoken with or messaged the same provider twice — no continuity of care